Hous­ton start­up paus­es en­roll­ment in pe­di­atric can­cer tri­al af­ter pa­tient death

A small Hous­ton biotech is hit­ting the brakes on an ear­ly clin­i­cal tri­al af­ter a pa­tient’s death.

Salarius Phar­ma­ceu­ti­cals paused new pa­tient en­roll­ment in a Phase I/II tri­al af­ter an in­di­vid­ual died tak­ing an ex­per­i­men­tal ther­a­py in­tend­ed to treat cer­tain sar­co­mas, the com­pa­ny an­nounced Tues­day. Pa­tients cur­rent­ly en­rolled can con­tin­ue tak­ing the ther­a­py for now, Salarius said, and ex­ecs have re­port­ed the de­tails to the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER